RPG Life Sciences launches Naprosyn ES, a first-in-India Naproxen-Esomeprazole combination
The product targets patients on long-term NSAID therapy who face elevated risk of gastrointestinal complications.
Read the full articleYou might also wanna read
RPG Life Sciences Launches Naprosyn ES in India; Firm Reports 14% Net Profit Growth
RPG Life Sciences enters an exclusive marketing agreement with Archerchem to launch Naprosyn ES, a value-added pharmaceutical combination ta
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
Conditions : Gastrointestinal Neoplasms Interventions : Drug: Velzatinib Sponsors : GlaxoSmithKline Not yet recruiting
GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer
GSK announced submission of MAA to EMEA for pazopanib, oral therapy for metastatic renal cell carcinoma (RCC).
Aragen partners with Renaissance Pharma to manufacture rare disease therapy
The biotech firm produced its first commercial-scale GMP batches of lead-candidate Daretabart.
Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)
Conditions : Ischemic Stroke; Ischemic Stroke, Acute; Transient Ischemic Attack (TIA); Cerebrovascular Disease; Gastrointestinal Complicatio
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre
chicagotribune.com·1mo agoExperimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre
chicagotribune.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.